Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Oct;368(4):324-7.
doi: 10.1007/s00210-003-0795-3. Epub 2003 Sep 6.

Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus

Affiliations

Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus

M J Cano-Cebrián et al. Naunyn Schmiedebergs Arch Pharmacol. 2003 Oct.

Abstract

Recently, we have shown that acamprosate is able to modulate extracellular dopamine (DA) levels in the nucleus accumbens (NAc) and may act as an antagonist of N-methyl-D-aspartate (NMDA) receptors. Neurochemical studies show that chemical stimulation (using NMDA) of the ventral subiculum (vSub) of the hippocampus produces robust and sustained increases in extracellular DA levels in the NAc, an effect mediated through ionotropic glutamate (iGlu) receptors. The present study examines whether acamprosate locally infused in the NAc of rats could block or attenuate the increase in NAc extracellular DA elicited by chemical stimulation (with 5 mM NMDA) of the ventral subiculum of the hippocampus. The stimulation of the vSub during perfusion of artificial cerebrospinal fluid in NAc induced a significant and persistent increase in NAc DA levels. Reverse dialysis of 0.05 mM acamprosate in NAc blocked the increase in DA evoked by the chemical stimulation of the vSub. These data support the possibility that the antagonism at the NMDA receptors in NAc can explain, at least in part, the mechanism of action of this drug.

PubMed Disclaimer

References

    1. Synapse. 1999 Mar 15;31(4):241-9 - PubMed
    1. J Neurosci. 2001 Jul 1;21(13):4915-22 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):119-25 - PubMed
    1. Psychopharmacology (Berl). 2003 Jul;168(1-2):99-108 - PubMed
    1. Brain Res Bull. 1997;42(4):303-8 - PubMed

MeSH terms

LinkOut - more resources